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breast cancer patients receiving anastrozole?
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Abstract
Background: BMI has been suggested to impact on estrogenic activity in patients receiving anastrozole resulting in
a reduced treatment efficacy in obese women. Current evidence in this regard is controversially discussed. Since
estradiol is inversely correlated with gonadotropins it can be assumed that an impact of BMI is also reflected by
gonadotropin plasma concentrations. We aim at investigating the impact of BMI on the hormonal state of breast
cancer (BC) patients receiving anastrozole indicated by LH, FSH and SHBG as well as estradiol.
Methods: We determined gonadotropin-, estradiol- and anastrozole- serum concentrations from postmenopausal,
early stage breast cancer patients receiving upfront anastrozole within routine after care. Gonadotropin plasma
concentrations were derived from the routine laboratory examination report. A liquid chromatography tandem
mass spectrometry method was used for the measurement of anastrozole serum concentrations. BMI was assessed
within the routine after-care check-up.
Results: The overall sample comprised 135 BC patients with a mean age of 65.3 years. BMI was significantly
correlated with LH, FSH and SHBG. This association was neither influenced by age nor by anastrozole serum
concentrations according to the regression model. Despite aromatase inhibition 12% of patients had
detectable estrogen levels in routine quantification.
Conclusion: Obese women have an altered hormonal situation compared to normally weight women
under the same dose of anastrozole. Our study findings are a further indicator for the relevance of BMI in
regard of anastrozole metabolism and possible estrogenic activity indicated by gonadotropin plasma level.
Keywords: Breast cancer, Gonadotropins, Body mass index, Estradiol, Aromatase inhibitor
Background
The observation of interindividual differences regarding
aromatase inhibitor (AI) metabolization has moved re-
search to the question of who benefits most from this adju-
vant treatment for breast cancer (BC) [1]. The search for
differential factors influencing treatment efficacy [2] has re-
cently identified the issue of BMI as an important factor
related to AI metabolization. In the ABCSG-12 study an in-
creased BMI has been associated with an increased risk for
disease recurrence and mortality in premenopausal women
receiving goserelin and anastrozole [3]. However, this effect
was not observed in the tamoxifen treated group. These re-
sults have been supported by others [4, 5]. However, also
the ABCSG-6a trial, investigating extended aromatase in-
hibitor treatment (AT), proved BMI to predict outcome
benefit in favour of normally weight women. The relevance
of BMI regarding AT has also been illustrated by the au-
thors by investigating the pharmacokinetic aspects of ana-
strozole in relation to BMI indicating an obesity related
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anastrozole metabolization [6]. Based on the well-known
association of obesity and increased overall estrogenic activ-
ity resulting in higher baseline estrogen values compared to
normal weight women [7], it has been suggested that
plasma estrogen levels might be insufficiently suppressed in
obese women when following standard AI dosing recom-
mendations. This hypothesis was supported only recently
by Folkerd and colleagues [8] who demonstrated that BMI
is related to levels of estrogen suppression. Obese women
had not only greater levels of estrogen at baseline but also
within the course of treatment. However, this was signifi-
cant only for the letrozole group. Additionally, information
on AI serum concentrations has been lacking which might
be a mediating factor in this regard. Finally, the measure-
ment of estradiol has been challenging due to a lack of as-
says with adequate functional sensitivity [9] which is
another limiting factor in this study.
Based on the above-mentioned observations and the
well-known inverse association of estradiol and gonado-
tropins [10–12], it can be assumed that the potential influ-
ence of BMI is also reflected by levels of gonadotropin
plasma concentration. Gonadotropins might act as a sur-
rogate marker for estrogenic activity that could be easily
determined in routine laboratory analysis.
We, thus, aim in this study to investigate the impact of
BMI on the hormonal state in a group of postmenopausal
BC patients receiving endocrine treatment with anastro-
zole in routine aftercare. This includes the determination
of gonadotropin (LH, FSH, Sex hormone binding
globulin-SHBG) and estradiol plasma levels considering
anastrozole serum concentrations. This analysis supple-
ments the work of the authors previously published [6].
Methods
The Ethics Committee of Medical University of Innsbruck
approved the study: Study number UN3648, 277/4.9.
Sample
For the study presented herein, data were derived from a
sample of BC patients treated at the Outpatient Unit of
the Department of Gynaecology and Obstetrics Medical
University Innsbruck, which has been published previ-
ously [6, 13]. From this overall sample of 242 BC patients
receiving anastrozole, only postmenopausal patients were
included in the pharmacokinetic or endocrine analysis to
provide group homogeneity (n = 7 were excluded from
the original sample as done in the analysis previously re-
ported [6]). From the remaining 235 postmenopausal pa-
tients information on the hormonal status was available
for 135 patients. Consequently, a final sample of 135 post-
menopausal BC patients receiving anastrozole was in-
cluded in the analysis. No group differences between
patients with vs. without hormonal data were found
regarding clinical or sociodemographic variables. Logistic
reasons account for the missing values.
As described previously [6, 13] eligible patients were
identified by searching the medical records and included
in the study at one of their routine follow-up visits. All
participating patients provided written informed consent.
After approval of study participation additional blood
samples for the determination of anastrozole plasma con-
centration as well as the hormonal status (estradiol, go-
nadotropins) were collected in the course of the patients’
routine blood examination. BMI was assessed within the
routine after-care check-up. Patient characteristics such as
age, menopausal status and clinical variables were derived
from the medical records. Sociodemographic and clinical
variables are routinely up-dated at every patient visit. The
patient’s menopausal status is routinely determined at the
clinical appointment by use of laboratory analysis of hor-
mones as well as clinical exploration (clinical indicators
for menopause) and is recorded in the medical history.
Analytical procedure
Analysis of anastrozole levels
A liquid chromatography-tandem mass spectrometry
method was used for the determination of anastrozole
serum concentrations. Please find details on the analytical
procedure for the determination of anastrozole serum con-
centrations elsewhere (Beer et al. 2012). Human plasma
samples were processed with a solid-phase extraction (SPE)
procedure on polymeric mixed-mode columns (Strata X-C,
200 mg/3 ml, Phenomenex, Torrance, CA, USA). Chroma-
tographic separation was accomplished on a reversed-phase
column (Si-C18, 5 μm, 200 × 0.5 mm i.d.) using a gradient
of acetone in an aqueous heptafluorobutyric acid solution.
Tandem mass spectrometric detection was performed on a
quadrupole-quadrupole linear ion trap instrument (3200 Q
Trap, AB Sciex, Foster City, CA, USA) scanning for mul-
tiple transitions. Validation included the assessment of se-
lectivity, linearity of the calibration model, accuracy and
precision, limit of quantification, recovery and matrix ef-
fects, processed sample stability, freeze and thaw stability,
and carryover. Within the concentration range 5 to 200 ng/
ml, intra- and inter-day precision and accuracies were al-
ways better than 15%. A more detailed description can be
found elsewhere (Beer et al. 2012).
Determination of LH, FSH, SGBH und Estradiol
LH and FSH were measured in serum samples using the
IMMULITE 2000 LH and IMMULITE 2000 FSH chemilu-
minescent immunometric assay kits (Siemens Healthcare
Diagnostics, Llanberis, UK), respectively. Analytical sensi-
tivities were 0.05 mIU/mL for LH and 0.1 mIU/mL for
FSH. Mean intra-assay coefficients of variation were 3.8%
for LH and 3.4% for FSH; mean inter-assay coefficients of
variation were 9.1% for LH and 5.4% for FSH. SHBG was
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measured in serum samples using the IMMULITE 2000
SHBG chemiluminescent immunometric assay (Siemens
Healthcare Diagnostics, Llanberis, UK). Analytical sensitiv-
ity was 0.02 nmol/L. Mean intra-assay coefficient of vari-
ation was 3.1%, inter-assay coefficient of variation was 5.0%.
17β Estradiol was measured in serum samples using a
COBAS electro-chemiluminescence Estradiol II immuno-
assay (Roche, Mannheim, Germany). Limit of quantification
was 12 ng/L. For human serum, intra-assay coefficients of
variation ranged from 1.7 to 3.3%, inter-assay coefficients of
variation ranged from 2.2 to 4.7%. Patients undergoing ana-
strozole treatment are expected to show estradiol levels
below the limit of quantification.
Statistical analysis
Sample characteristics are presented as frequencies,
means, standard deviations and ranges. Variables were
scrutinized for their distribution (normality) by use of the
Shapiro Wilk test, descriptive parameters (mean, median,
skewness) and the histogram. For the non-normally dis-
tributed variables SHBG and BMI a logarithmic trans-
formation was applied to achieve an approximately
normal distribution. Estradiol was measured as a continu-
ous variable as the essay allows indicating values equal to
and above 12 ng/L. For our analysis we grouped the vari-
able dichotomously (≤12 vs. >12 ng/L) as the majority of
patients showed values below the limit of quantification
(12 ng/L). The overall association of BMI with estrogen
and gonadotropin plasma concentrations was analyzed
using spearman rank correlation (also for parametric vari-
ables to provide consistency across tests). We further in-
vestigated the predictive value of BMI for gonadotropin
plasma levels under consideration of age using a linear re-
gression analysis. For the prediction of estrogen (grouped
variable) levels by BMI we used a logistic regression
model. In a second step, anastrozole plasma levels were
included in the regression models as independent variable.
A p value of <0.05 was considered significant.
Sample size consideration
A sample size of 135 is sufficiently large to detect, under
standard conditions regarding type-one error (alpha = 0,05)
and statistical power (1-beta =0.8), correlation coefficients
above 0.238 or below −0.238. Sample size calculation was
performed by use of G-Power 3.1.7.
Results
Patient characteristics
Patients (n = 135) were aged 65.3 years on average
(range 47-85 years) and had been undergoing endocrine
treatment for a mean duration 29.5 (SD 17.3) months.
Median BMI was 25.5, with a range of 24.2. Please find
further details on clinical and sociodemographic patient
characteristics in Table 1.
Analysis of anastrozole serum levels
Measurement of anastrozole concentrations in serum
showed a median level of 32.8 ng/ml (range = 76.08 ng/
Table 1 Clinical and sociodemographic patient characteristics
n = 135
Frequency (%)
Age Mean (SD) 65.3a (8.5a)
Range 47-85
Marital status Single 8 (5.9%)
Partnership, marriage 70 (51.9%)
Divorced, separated 20 (14.8%)
Widowed 18 (13.3%)
Employment status Full time 7 (5.2%)









Mean (SD) 29.5 (17.3)
Range 2.5-70.8
Primary surgical treatment Breast conserving surgery 87 (64.9)
Mastectomy 47 (35.1)
Chemotherapy yes 27 (20%)
Radiotherapy yes 98 (72.6%)
BMI Mean (SD) 25.2 (4.3)
Median 25.2
range 19.5-43.7
Estradiol ≤12 119 (88.1%)
>12 16 (11.9%)
Median 12 ng/L
Minimum-Maximum <12 -69 ng/L
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ml, Min: 10.42 ng/ml, Max. 86.5 ng/ml). The compound
was detected in all patients.
Association of estrogen and gonadotropin plasma levels
with BMI
We found a significantly negative correlation of BMI with
LH, FSH and SHBG (Fig. 1). BMI and estradiol were not
significantly correlated (see Table 2). However, this might
be due to limitations in the analysis of estradiol levels.
LH, FSH and SHBG did not achieve a correlation at a
0.05 significance level with estradiol but a considerable
trend towards significance was observed for FSH and
SHBG (FSH: r = −0.147, p = 0.088; SHBG: r = −0.165,
p = 0.063). Again this observation is a result of the limited
sensitivity of the estradiol assay.
In a linear regression analysis we investigated the joined
effect of BMI and age on LH, FSH and SHBG. BMI signifi-
cantly predicted levels of LH and SHBG as follows: Per
unit increase of BMI, LH decreased by an average of
0.562 units and SHBG by 2.4%, respectively. As expected,
a lack of association of BMI and estradiol was confirmed
also in the logistic regression analysis. We did not find an
impact of age on LH and SHBG. However, after control-
ling for age in the model for FSH, BMI failed to reach stat-
istical significance but stayed in the model showing a
trend that approached significance (p = 0.055). In accord-
ance with expectations no predictive value of age in
addition to BMI on estradiol concentrations was found.
Please find details in Tables 3 and 4.
Also the addition of anastrozole plasma concentration
as an independent variable did not contribute to the re-
gression models.
Finally, analysis revealed a trend towards significance for
the association of estradiol with FSH (r = −0.147,
p = 0.088) and SHBG (r = 0.-165, p = 0.063) but not for LH
(r = 0.00, p = 0.990).
Discussion
Several studies have identified BMI as a crucial factor for
BC genesis, cancer subtype, treatment response and fi-
nally outcome [6, 14–18]. This observation probably orig-
inates from increased estrogen plasma concentrations
related to overweight [7]. Regarding endocrine treatment
with AIs recent evidence suggests that also during the in-
take of standardly dosed AIs these increased estrogen
levels persist and, thus, contribute to the reduction of
treatment efficacy [3, 5, 8]. However, these results are cur-
rently controversially discussed [19]. Studies available are
limited by standard measurement methods for estradiol
which lack functional sensitivity [9]. Additionally, these
methods are usually cost intensive. There is a lack of data
on other biological effects of anastrozole beside estrogen
suppression [10].
The present study was subjected to getting a more com-
prehensive picture of the impact of BMI on the hormonal
state in postmenopausal patients receiving anastrozole in
routine clinical care. We assumed that gonadotropins (LH,
FSH, SHBG) might act as surrogate marker for estrogenic
activity and also considered anastrozole serum
Fig. 1 Association of BMI with gonadotropins (LH, FSH) and SHBG (n = 135) determined by use of Spearman Rank Correlation
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concentrations as a mediating factor. We also hypothesized
that estradiol levels are less important than “estrogenic ac-
tivity”, which is defined as any stimulation of the estrogen
receptor by various molecules including precursors and
metabolites of estradiol. There is also accumulating evi-
dence that various agents and drugs may also exhibit bio-
logical activity on the estrogen receptor. This means that
several, yet unknown compounds besides steroid hormones
might have activity on the estrogen receptor in patients
under aromatase inhibitor treatment (AT).
In fact, we found serum gonadotropin levels (LH, FSH
and SHBG) [9] to be significantly lower in obese women
compared to normally weight women under AT. This result
persisted independently of age. Since gonadotropins are ex-
pected to increase in association with decrease of estrogen
it can be assumed that BMI impacts on estrogenic activity
under AT. So far, obesity has been well-known to be related
to higher estrogen serum concentrations only in women
without a BC diagnosis/treatment [10, 18], yet under endo-
crine treatment an approximation to homogenous estrogen
and gonadotropin levels of serum concentrations had been
expected regardless of BMI. According to our results post-
menopausal, obese women, still have a differing endocrine
situation compared to normally weight women despite re-
ceiving anastrozole treatment (AT). Our results are sup-
ported by a recent study of Pfeiler and colleagues [20] who
prospectively investigated levels of estradiol suppression
related to BMI as well as FSH serum concentrations in
adjuvant-treated postmenopausal patients with BC. The au-
thors also found significantly lower FSH levels in obese
women compared to normally weight women. Still, a very
recent study determining estradiol over a period of
24 months showed contradictory results [21]. The initial,
well-known difference of estradiol serum concentrations
between overweight and normally weight women did not
persist to the 12- and 24-month follow-up assessment
under endocrine treatment. However, overweight women
had increased estradiol levels at all time-points. Results
thereafter might be influenced by a quite small overall sam-
ple size of 70. Information on gonadotropin levels might
have had additional explanatory benefit.
Another notable finding herein is that we were able to
demonstrate that levels of anastrozole serum concentra-
tions do not have a mediating effect on estrogenic activity.
This is particularly of importance since anastrozole serum
concentrations proved to be related to BMI in this patient
sample. Detailed results in this regard have been presented
[6]. This again strengthens the significant role of BMI with
regard to the patient’s hormonal situation under AT.
We did not find a significant association of BMI and es-
tradiol measured by a routine laboratory assay. This result
was somehow expected and can be explained by two
major reasons: First, it has been previously reported that
serum estradiol levels do not correlate with BMI [3, 7, 17]
and estradiol measurement within breast tissue might bet-
ter reflect aromatase activity. Second, we lacked a hyper-
sensitive assay for estradiol measurement and derived the
hormonal data from the routine laboratory examination
report based on an assay with low sensitivity.
However, the measurement of estradiol has been previ-
ously challenging [9]. Mass spectrometry methods seem to
be currently the only estradiol assays showing satisfactory
sensitivity; but this method is labor- and cost- intensive and
difficult to integrate into clinical routine. Finally, also Pfeiler
and colleagues were not able to illustrate a significant asso-
ciation of BMI and levels of estradiol [20].
Table 2 Correlation of BMI with estradiol and gonadotropins
(n = 135)




LH - 0.225 0.018
FSH - 0.260 0.006
SHBG - 0.312 0.001
Table 3 Linear Regression model with the independent variables BMI and age
Dependent variable Regression coefficient ANOVA
Unstandardized beta Standardized beta p-value F p-value
LH 7.472 0.007*
BMIa −0.562 −0.255 0.007*
Age 0.838
FSH 6.862 0.002*
BMIa −1.2 −0.181 0.055
Age −0.837 −0.252 0.008*
SHBGa 6.364 0.013*
BMIa −0.024 −0.245 0.013*
Age 0.132
aLogarithmic transformed
*considered significant indicated by a significance level p ≤ 0.05
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Conclusion
In view of our results, the previously observed impact of
BMI on the hormonal situation in women under AT
seems to be reflected also by gonadotropin concentrations;
as we had a adequately powered sample and were able to
exclude confounding factors such as anastrozole serum
concentrations our findings might further support the no-
tion [3, 20] that estrogens are insufficiently suppressed in
obese women.
At this point, our study findings are a further indicator
for the relevance of BMI in regard of anastrozole metabol-
ism and in conjunction treatment efficacy. Though not
answered yet, the question whether increased estrogen
levels in obese women undergoing AT are responsible for
a reduced treatment efficacy has been brought forward.
Other potential explanatory factors such as insulin, adipo-
cytokines such as leptin, and adiponectin, as well as in-
flammatory markers such as C-reactive protein and
interleukins will have to be additionally investigated. We
suggest the observation of gonadotropin plasma concen-
tration to be a cheap and useful surrogate parameter in
clinical routine for the monitoring of patients’ treatment
response. However, still more studies are necessary to im-
plement this observation to clinical practice.
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